U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07739888) titled 'Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation' on July 28.
Brief Summary: This OLE part is an optional, single arm, multicenter, open-label extension (OLE) added to the core part to assess the long-term safety, tolerability, the incidence of ischemic stroke or SE and bleeding events of abelacimab in eligible patients who completed the double-blinded core part of CMAA868A2302 (ANT-010/NCT05712200)
Study Start Date: Dec. 30, 2027
Study Type: INTERVENTIONAL
Condition:
Atrial Fibrillation (AF)
Intervention:
BIOLOGICAL: ...